Anaplastic lymphoma kinase (ALK) fusion has been identified in 3% to 7% of patients with non–small-cell lung cancer (NSCLC), and such patients benefit greatly from ALK tyrosine kinase inhibitors (ALK-TKIs). The most common ALK fusion is echinoderm microtubule-associated protein-like 4 (EML4)-ALK, and several variants that are generally sensitive to crizotinib exist.1 In recent years, other fusion types sensitive to crizotinib, such as DYSF&ITGAV-ALK, BCL11A-ALK, and BIRC6-ALK, have been discovered by next-generation sequencing (NGS).2, 3, 4, 5, 6 However, a WD (Trp-Asp) planar cell polarity (PCP) effector gene (WDPCP)-ALK fusion has not been previously published. Here, we report this novel WDPCP-ALK fusion, which is sensitive to crizotinib, in a patient with lung adenocarcinoma. READ ARTICLE
Clinical Lung Cancer DOI:10.1016/j.cllc.2019.06.001
Authors: Zhen He, Xuan Wu, Shuxiang Ma, Cuicui Zhang, Zhe Zhang, Shuai Wang, Sheng Yu, Qiming Wang
